Beyond immediate kidney rescue, glucarpidase's crucial role is preserving a patient's eligibility for subsequent methotrexate cycles. This allows them to complete their planned, first-line cancer treatment, giving them the best chance at remission—a benefit not captured by short-term outcomes.

In muscle-invasive bladder cancer, cisplatin ineligibility is frequently due to renal insufficiency caused by large, aggressive tumors obstructing the ureter. This redefines this patient group as having more advanced local disease, rather than simply being unfit for chemotherapy, explaining their poor outcomes with surgery alone.

Despite the perception that cisplatin-ineligible patients have worse disease biology, the pathologic complete response rates to neoadjuvant EV Pembro were nearly identical (56-57%) in both cis-ineligible (KEYNOTE-905) and cis-eligible (KEYNOTE-B15) trials. This suggests the regimen's high efficacy may overcome underlying biological differences.

When a highly effective therapy like EV Pembro was approved for 'cisplatin ineligible' patients, the definition of 'ineligible' became very elastic in practice. This demonstrates that when a new treatment is seen as transformative, clinicians find ways to qualify patients, putting pressure on established guidelines.

The term "platinum-resistant" is being replaced by "platinum-ineligible" because the traditional 6-month relapse cutoff is an arbitrary and poor predictor of treatment response. The new term more accurately identifies patients who progress during or immediately after platinum therapy, acknowledging that others may still benefit.

The clinical lexicon for recurrent ovarian cancer is evolving. The term "platinum resistant" is being replaced by "platinum ineligible." This reflects a more nuanced clinical judgment that platinum-based chemotherapy is not the best option for a patient's recurrence, rather than being based solely on a time-defined interval of relapse.

While new systemic agents dominate MIBC discussions, chemo-radiation remains a critical treatment, especially for patients unsuitable for radical cystectomy due to age or comorbidities. For these individuals, it offers a potentially curative, bladder-preserving alternative that avoids the high risks and sequelae of major surgery.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

The demonstrated superiority of the enfortumab vedotin (EV) and pembrolizumab combination over platinum chemotherapy has effectively made the Galski criteria, used for determining cisplatin eligibility, irrelevant. This marks a major paradigm shift in how frontline bladder cancer is approached, moving beyond platinum-based decisions.